Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wanting Lei

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Molecular Biomedicine|January 9, 2025
Cancer vaccines: platforms and current progressWanting Lei, Kexun Zhou, Ye Lei, et al.
NPJ Biofilms and Microbiomes|July 27, 2025
Gut microbiota shapes cancer immunotherapy responsesWanting Lei, Kexun Zhou, Ye Lei, et al.
Molecular Cancer Therapeutics|October 17, 2024
Pathogenesis and Systemic Treatment of Hepatocellular Carcinoma: Current Status and ProspectsWanting Lei, Kexun Zhou, Ye Lei, et al.
Cardiovascular Diabetology|June 6, 2026
Associations of cumulative exposure and dynamic trajectories of the combined atherogenic and frailty index with incident cardiometabolic multimorbidity: a longitudinal analysis based on the China Health and Retirement Longitudinal Study (CHARLS)Xianjing Feng, Bi Deng, Yinghuan Pan, et al.
Advances in Therapy|October 19, 2021
Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United StatesWeiting Liao, Wanting Lei, Mingyang Feng, et al.
Frontiers in Oncology|March 29, 2021
The Effects of Autophagy-Related Genes and lncRNAs in Therapy and Prognosis of Colorectal CancerYang Yang, Mingyang Feng, LiangLiang Bai, et al.
Therapeutic Advances in Medical Oncology|September 20, 2024
Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinomaWeiting Liao, Huiqiong Xu, David Hutton, et al.
Frontiers in Oncology|December 23, 2021
Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal TumorsWeiting Liao, Huiqiong Xu, David Hutton, et al.
Cancer Immunology, Immunotherapy : CII|March 10, 2021
The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyteBaojuan Han, Lina Dong, Jing Zhou, et al.
Oncotarget|December 31, 2016
Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytesJingxuan Wang, Kun Gao, Wanting Lei, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Molecular Biomedicine|January 9, 2025
Cancer vaccines: platforms and current progressWanting Lei, Kexun Zhou, Ye Lei, et al.
NPJ Biofilms and Microbiomes|July 27, 2025
Gut microbiota shapes cancer immunotherapy responsesWanting Lei, Kexun Zhou, Ye Lei, et al.
Molecular Cancer Therapeutics|October 17, 2024
Pathogenesis and Systemic Treatment of Hepatocellular Carcinoma: Current Status and ProspectsWanting Lei, Kexun Zhou, Ye Lei, et al.
Cardiovascular Diabetology|June 6, 2026
Associations of cumulative exposure and dynamic trajectories of the combined atherogenic and frailty index with incident cardiometabolic multimorbidity: a longitudinal analysis based on the China Health and Retirement Longitudinal Study (CHARLS)Xianjing Feng, Bi Deng, Yinghuan Pan, et al.
Advances in Therapy|October 19, 2021
Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United StatesWeiting Liao, Wanting Lei, Mingyang Feng, et al.
Frontiers in Oncology|March 29, 2021
The Effects of Autophagy-Related Genes and lncRNAs in Therapy and Prognosis of Colorectal CancerYang Yang, Mingyang Feng, LiangLiang Bai, et al.
Therapeutic Advances in Medical Oncology|September 20, 2024
Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinomaWeiting Liao, Huiqiong Xu, David Hutton, et al.
Frontiers in Oncology|December 23, 2021
Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal TumorsWeiting Liao, Huiqiong Xu, David Hutton, et al.
Cancer Immunology, Immunotherapy : CII|March 10, 2021
The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyteBaojuan Han, Lina Dong, Jing Zhou, et al.
Oncotarget|December 31, 2016
Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytesJingxuan Wang, Kun Gao, Wanting Lei, et al.
Pageof 2